Rheumatoid Arthritis: Modern Treatment Strategies and Risk Management
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints, causing pain, swelling, stiffness, and eventually joint destruction. However, its impact extends beyond the musculoskeletal system, affecting various bodily systems and significantly increasing the risk of comorbidities. Modern approaches to RA treatment are aimed not only at reducing inflammation and preventing joint damage, but also at managing systemic complications, which requires a comprehensive and individualized strategy [7].
Basics of Rheumatoid Arthritis Treatment: Disease-Modifying Antirheumatic Drugs
The foundation of rheumatoid arthritis treatment is disease-modifying antirheumatic drugs (DMARDs). These medications slow down disease progression, reduce inflammation, and prevent joint damage. The choice of a specific drug and treatment regimen is always individualized and depends on the severity of the disease, its activity, the presence of comorbidities, and the patient's response to therapy [7].
Interestingly, in addition to their direct effect on rheumatoid arthritis, DMARDs may play a role in reducing the risk of developing other autoimmune diseases. For example, studies show that RA patients receiving DMARDs may have a reduced risk of developing autoimmune thyroid disease (AITD). RA and AITD share common genetic factors, and the prevalence of AITD among RA patients is higher than in the general population. However, a large cohort study in Sweden showed that after an RA diagnosis, the incidence rate of AITD development in RA patients was lower (3.7 per 1,000 person-years) compared to the general population (4.6 per 1,000 person-years), corresponding to a 19% risk reduction [1]. This suggests that the immunomodulatory effect of DMARDs may have a protective effect.
Biologic and Targeted Therapy: New Horizons
For patients in whom standard DMARDs do not provide adequate disease control, biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used. These drugs act more targetedly on specific components of the immune system involved in the development of RA.
One example of biologic therapy is rituximab, a drug aimed at B-cell depletion. It has proven effective in refractory rheumatoid arthritis, meaning cases where other treatments do not yield the desired result. Research continues to improve B-cell depletion strategies, possibly through enhanced depletion or sequential therapy with other drugs, such as belimumab, to achieve better clinical responses [6].
The use of bDMARDs and tsDMARDs is also being studied in the context of their impact on systemic risks associated with RA, such as cardiovascular diseases [3].
Managing Comorbid Risks: Cardiovascular Diseases
Rheumatoid arthritis significantly increases the risk of developing cardiovascular diseases, including myocardial infarction (MI). A national cohort study conducted in Korea showed that RA patients have an almost 1.8-fold higher risk of developing myocardial infarction compared to people without RA. This increased risk is observed in both seropositive and seronegative RA patients [3].
Given this fact, comprehensive RA treatment must necessarily include active management of cardiovascular risks. An important aspect is the control of dyslipidemia (lipid metabolism disorders), which is frequently found in RA patients. Statins, developed to treat lipid metabolism disorders, have proven effective in reducing cardiovascular morbidity and mortality. Although their direct beneficial effect on RA itself remains unproven, they play a key role in preventing cardiovascular complications in this patient group. Therefore, all RA patients should regularly undergo lipid profile tests, and if dyslipidemia is detected, statin therapy should be prescribed in accordance with current guidelines [2].
Individualized Approach and Comprehensive Strategy
Successful rheumatoid arthritis therapy requires an individualized approach, selecting the right drug for a specific patient taking into account their condition and disease stage [7]. RA treatment is not simply prescribing a single drug, but a comprehensive strategy that may include:
- Early initiation of therapy: The earlier adequate treatment is started, the better the prognosis.
- Step-down approach: Starting with milder, well-tolerated anti-inflammatory drugs for mild cases, moving to more effective but potentially more toxic drugs for severe courses or lack of response [7].
- Long-term therapy: For patients unresponsive to previous measures, slow-acting, long-term agents are used [7].
- Corticosteroids: Can be used for rapid relief of flares and reduction of inflammation, but their long-term use is limited due to side effects [7].
- Non-pharmacological methods: Physiotherapy, exercise therapy, orthoses, and, if necessary, surgical intervention.
- Psychological support: Assistance in adapting to a chronic disease.
The goal of treatment is to achieve remission or low disease activity, improve quality of life, preserve joint function, and prevent systemic complications.
Sources
- Disease-modifying antirheumatic drugs and risk of thyroxine-treated autoimmune thyroid disease in patients with rheumatoid arthritis.
- Statins in rheumatology.
- Rheumatoid arthritis and risk of myocardial infarction: A nationwide cohort study.
- Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.
- Which antirheumatic drug?
The information provided in this article is for informational purposes only and should not be used for self-diagnosis or self-treatment. Always consult a qualified medical professional for diagnosis and selection of an optimal treatment plan.